PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5964142

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	SECURITY INTEREST
RESUBMIT DOCUMENT ID:	505751061

CONVEYING PARTY DATA

Name	Execution Date
ENEURA, INC.	10/25/2019

RECEIVING PARTY DATA

Name:	CAMDEN PARTNERS NEXUS FUND, L.P.
Street Address:	500 E. PRATT STREET, SUITE 1200
City:	BALTIMORE
State/Country:	MARYLAND
Postal Code:	21202
Name:	WORLD TOTAL RETURN FUND, LLLP
Street Address:	233 E. REDWOOD STREET, SUITE 100
City:	BALTIMORE
State/Country:	MARYLAND
Postal Code:	21202

PROPERTY NUMBERS Total: 12

Property Type	Number
Patent Number:	8740765
Patent Number:	9968798
Patent Number:	10029112
Patent Number:	9526912
Patent Number:	9561384
Patent Number:	9675815
Patent Number:	9724533
Application Number:	14147673
Application Number:	14148932
Application Number:	14451636
Application Number:	62088402
Application Number:	14959275

CORRESPONDENCE DATA

PATENT REEL: 051827 FRAME: 0637

505917425

Fax Number: (336)733-8473

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4105455827

Email: trademarkswinston@wbd-us.com

Correspondent Name: NICHOLAS B. HAWKINS

Address Line 1: WOMBLE BOND DICKINSON (US) LLP
Address Line 2: 100 LIGHT STREET, 26TH FLOOR
Address Line 4: BALTIMORE, MARYLAND 21202

ATTORNEY DOCKET NUMBER:	74681.0014.7
NAME OF SUBMITTER:	NICHOLAS B. HAWKINS
SIGNATURE:	/Nicholas B. Hawkins/
DATE SIGNED:	02/14/2020
	This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 8

source=Camden Partners - eNeura, Inc. - Patent Securtity Agreement#page1.tif source=Camden Partners - eNeura, Inc. - Patent Securtity Agreement#page2.tif source=Camden Partners - eNeura, Inc. - Patent Securtity Agreement#page3.tif source=Camden Partners - eNeura, Inc. - Patent Securtity Agreement#page4.tif source=Camden Partners - eNeura, Inc. - Patent Securtity Agreement#page5.tif source=Camden Partners - eNeura, Inc. - Patent Securtity Agreement#page6.tif source=Camden Partners - eNeura, Inc. - Patent Securtity Agreement#page7.tif source=Camden Partners - eNeura, Inc. - Patent Securtity Agreement#page8.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this "<u>Agreement</u>"), dated as of October 25, 2019 is entered into by eNeura, Inc., a Delaware corporation (the "<u>Grantor</u>"), and Camden Partners Nexus Fund, L.P. and World Total Return Fund, LLLP (each, a "<u>Lead Purchaser</u>" and collectively, the "<u>Lead Purchasers</u>"), on behalf of the Purchasers (the Purchasers, collectively, the "<u>Secured Party</u>").

Capitalized terms not otherwise defined herein have the meanings set forth in the Security Agreement dated as of October 25, 2019 among the Grantor and the Lead Purchasers.

WHEREAS, pursuant to the Security Agreement, the Grantor has granted a security interest to the Secured Party in certain Patents whether now owned or existing or hereafter acquired or arising and wherever located, including without limitation the patents listed on <u>Schedule A</u> ("<u>Secured Patents</u>").

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantor and the Secured Party hereby agree as follows:

(i) Grant of Security Interest.

- (a) The Grantor hereby grants to the Secured Party a security interest in, and continuing lien on, all of the Grantor's right, title and interest in, to and under all the Secured Patents, subject to the terms and conditions of the Security Agreement.
- (b) The security interest granted hereby is granted in conjunction with the security interest granted to the Secured Party under the Security Agreement. The rights and remedies of the Secured Party with respect to the security interest granted hereby are in addition to those set forth in the Security Agreement. In the event of any conflict between the terms of this Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall control.
- (c) The Grantor and Secured Party hereby acknowledge and agree that the security interest in the Secured Patents is not to be construed as an assignment of any patent or patent application.

(ii) Governing Law.

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE.

(iii) Successors and Assigns.

This Agreement shall be binding upon and inure to the benefit of the Secured Party and the Grantor and their respective successors and assigns. The Grantor shall not, without the prior written consent of the Secured Party, assign any right, duty or obligation hereunder.

1

(iv) <u>Counterparts</u>.

This Agreement may be executed in any number of counterparts and by the parties hereto on separate counterparts, each of which when so executed, shall be deemed to be an original and all of which taken together shall constitute one and the same instrument.

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

WBD (US) 47818469v2

IN WITNESS WHEREOF, the Grantor and the Secured Party have caused this Patent Security Agreement to be duly executed and delivered as of the date first above written.

GRANTOR:

eNeura, Inc.,	
a Delaware corporation	
By: David R. Fischell Title: Chairman	(SEAL)
LEAD PURCHASERS:	
Camden Partners Nexus II, LLC	
Ву:,	
its general partner	
Ву:	(SEAL)
Name: R. Jacob Vogelstein, PhD	
Title: General Partner	
World Total Return Fund, LLLP By:	
its general partner	
Ву:	(SEAL)
Name:	
Title:	

IN WITNESS WHEREOF, the Grantor and the Secured Party have caused this Patent Security Agreement to be duly executed and delivered as of the date first above written.

GRANTOR: eNeura, Inc., a Delaware corporation

By: (SEAL)

Name: David R. Fischell

Title: Chairman

LEAD PURCHASERS: CAMDEN PARTNERS NEXUS FUND, L.P.

By: Camden Partners Nexus, LLC, its General Partner by:

By:

Name: R. Jacob Vogelstein, PhD Title: Manager and Member

World Total Return Fund, LLLP

By: World Total Return Inc.,

its general partner

By: Y \m 5 7c

Name: Marc Blum Title: President

SIGNATURE PAGE TO PATENT SECURITY AGREEMENT

PATENT SECURITY AGREEMENT

I. U.S. REGISTERED PATENTS

Title	Owner	Pat. Application	Patent No.	Filing Date	Issue Date
Magnetic Pulsing System for Inducing Electric Currents in a Human Body	eNeura, Inc.	Serial No. 13/571,833	8,740,765	8/10/12	6/3/14
TMS device with body proximity sensors for the treatment of migraine headaches	eNeura, Inc.	14/315/994	9,968,798	6/26/14	5/15/18
Transcranial magnetic stimulation device for the treatment of migraine headaches	eNeura, Inc.	14/148,922	10,029,112	1/7/14	7/24/18
METHOD AND APPARATUS TO RECORD AND ANALYZE TMS TREATMENTS AND RESULTS	eNeura, Inc.	15831795A	20180345032 A1	12/05/17	12/06/18
Transcranial magnetic stimulation device for the treatment of migraine headaches	eNeura, Inc.	15347302A	9724533B1	11/09/16	8/08/17
Transcranial magnetic stimulation device for the treatment of migraine headaches	eNeura, Inc.	15347290A	9675815B1	11/09/16	6/13/17

WBD (US) 47818469v2

Title	Owner	Pat. Application	Patent No.	Filing Date	Issue Date
Transcranial	eNeura, Inc.	Serial No. 14/275,927	9,526,912	5/13/14	12/27/16
magnetic	crycura, mc.	14/2/3,72/	7,320,712	3/13/14	12/2//10
stimulation					
device for the					
treatment of					
migraine					
headaches*					
Transcranial	eNeura, Inc.	14/148,932	9,561,384	1/7/14	2/7/17
magnetic					
stimulation					
device for the					
treatment of					
migraine					
headaches*					
Transcranial	eNeura, Inc.	15/347/290	9,675,815	11/9/16	6/13/17
magnetic					
stimulation					
device for the					
treatment of migraine					
headaches*					
TMS device for	eNeura, Inc.	15/347,302	9,724,533	11/9/16	8/8/17
the treatment of	cricula, inc.	13/34/,302	7,724,333	11/5/10	0/0/17
Migraine					
Headaches*					
METHOD AND	eNeura, Inc.	15285249A	20170021188	1/04/16	1/16/17*
APPARATUS			A1		
TO RECORD					
AND					
ANALYZE TMS					
TREATMENTS					
AND RESULTS					

^{*}Abandoned

II. U.S. PATENT APPLICATIONS

Title	Owner	Pat. Application Serial No.	Patent No.	Filing Date	Issue Date
Transcranial magnetic stimulation device for treatment of migraine headaches	eNeura, Inc.	14/147,673	N/A	01/06/2014	05/15/2018

WBD (US) 47818469v2

Title	Owner	Pat. Application Serial No.	Patent No.	Filing Date	Issue Date
Transcranial magnetic stimulation device for treatment of migraine headaches	eNeura, Inc.	14/148,932	N/A	01/07/2014	N/A
Use of transcranial magnetic stimulation for improved sleep quality	eNeura, Inc.	14/451,636	N/A	08/05/2014	N/A
Preventative migraine headache treatment	eNeura, Inc.	62/088,402	N/A	12/05/2014	N/A
METHODS AND SYSTEMS FOR PREVENTATIV E MIGRAINE HEADACHE TREATMENT	eNeura, Inc.	US14959275A	N/A	12/04/2015	N/A

III. OTHER U.S. PATENT REGISTRATIONS

Title	Owner	Par. Application Serial No.	Patent No	Filing Date	Issue Date
Magnetic Pulsing	Neuralieve,	11/305,276	8,262,556	12/19/05	9/11/12
System for	Inc.				
Inducing Electric					
Currents in a					
Human Body					
Method and	Neuralieve,	12/718,163	9,492,680	3/5/10	11/15/16
Apparatus to	Inc.				
record and					
analyze TMS					
treatments and					
results*	XT 1'	00/620 210	C 102 CT0	7/21/ 00	6/11/00
Means and	Neuralieve,	09/629,210	6,402,678	7/31/00	6/11/02
method for the	Inc.				
treatment of					
migraine headaches					
	Nouropass	15/127 670	0.604.105	4/25/16	7/4/17
Low frequency neurostimulator	Neuropace, Inc.	15/137,670	9,694,195	4/25/16	//4/1/
for the treatment	IIIC.				
of neurological					
disorders					
GISSIGOIS		l			

WBD (US) 47818469v2

Means and methods for treating headaches	Neuropace, Inc.	10/327,163	7,294,101	12/21/02	11/13/07
Means and methods for treating headaches	Neuropace, Inc.	11/974,712	7,494,458	2/24/09	2/24/09
Low Frequency Magnetic Neurostimulator for the Treatment of Neurological Disorders	Neuropace, Inc.	11/436,676	7,601,116	5/16/06	10/13/09
Low frequency neurostimulator for the treatment of neurological disorders	Neuropace, Inc.	12/549,303	9,033,861	8/27/09	5/19/15
Low frequency neurostimulator for the treatment of neurological disorders	Neuropace, Inc.	14/688,935	9,352,168	4/16/15	5/31/16

WBD (US) 47818469v2

RECORDED: 10/31/2019